

SETTLEMENT AGREEMENT AND RELEASE

This Settlement Agreement (the "Agreement") is entered into by and between the plaintiff State of Iowa, by and through its Attorney General Tom Miller, and the defendants Dey, L.P. and Dey, Inc. (the State and Dey shall be collectively referred to as the "Parties"). The Parties, through their authorized representatives agree as follows:

Section I. Preamble

- A. The State of Iowa shall be referred to as the "State."
- B. DEY, Inc. is a corporation organized under the laws of Delaware; DEY, L.P. is a limited partnership organized under the laws of Delaware, and is owned by Dey, Inc., and Dey Limited Partner, Inc. Dey, Inc., Dey, L.P., and Dey Limited Partner, Inc. shall collectively be referred to as "Dey" for purposes of this Agreement.
- C. All references to Dey herein include acts individually, in concert, or by or through employees, agents, representatives, affiliates, assignees and successors.
- D. On October 9, 2007, the State commenced an action in the United States District Court for the Southern District of Iowa, Central Division, against Dey entitled *State of Iowa v. Abbott Laboratories, Inc., et al.* (Orig. Case No. 07-00461) (the "Litigation").
- E. Dey expressly denies any wrongdoing, and the State acknowledges that Dey has denied any wrongdoing. This Agreement does not constitute an admission of fault or liability by Dey, nor does it constitute evidence of any liability or unlawful conduct on the part of Dey.
- F. The Parties further acknowledge that this settlement is intended to resolve the "Covered Conduct" claims concerning only the State of Iowa and its Medicaid Agency.
- G. This Agreement is the product of a compromise between Dey and the State and the amount of the settlement is based on the Parties' respective assessments of numerous factors and issues relating to the Litigation. The Agreement and the amount of the settlement therefore is

not intended by the parties hereto to be cited by any non-party to the Agreement as evidence supporting any position.

H. The State does not waive its right to participate in and receive its pro rata share of any settlement proceeds or other consideration from Dey pursuant to any settlement agreement, memoranda of understanding, consent order, or any other form of resolution with the National Association of Medicaid Fraud Control Units to the extent that such resolution does not duplicate payments made through this Agreement for Covered Conduct.

I. In order to avoid the delay, uncertainty, inconvenience and expense of continuing the Litigation of the State's claims against Dey, and as a result of a mutual desire to settle their disputes, the Parties have reached a full and final settlement as set forth in this Agreement.

J. The State represents that no interest in its claims set forth in the Litigation against Dey have been assigned by the State to any third party.

K. Having read and understood the terms and conditions of this Agreement, the Parties agree that this Agreement constitutes a fair resolution of the Parties' disputes. The Parties have had the opportunity to consult with legal counsel regarding this Agreement, and agree to be bound by all provisions contained herein.

Section II. Terms and Conditions

NOW THEREFORE, for the mutual promises, covenants and obligations set forth below, and for the good and valuable consideration as stated herein, the receipt and sufficiency of which is hereby acknowledged, the State and Dey agree as follows:

1. The foregoing Preamble is incorporated herein.

2. This Agreement is intended to cover the pharmaceutical products manufactured and/or sold by Dey, as set forth in Appendix A. The pharmaceutical products listed in Appendix A are referred to hereafter as the “Covered Drugs.”

3. The “Covered Conduct” that is addressed by this Agreement is all conduct: (a) that the State did allege in the Litigation; or (b) could have alleged in the Litigation relating to Dey’s reporting, prior to the Effective Date, of Average Wholesale Price (“AWP”) Wholesale Acquisition Cost (“WAC”), or Direct Price (“DP”), or the marketing of any alleged spread between AWP and Actual Acquisition Cost with respect to any of the Covered Drugs.

The Settlement Payments

4. Dey agrees to pay the State the total sum of one million eight hundred thousand dollars (\$1,800,000) as full and final payment of restitution and compensatory damages related to the Covered Conduct for all Covered Drugs, administrative fees and costs (the “Settlement Amount”). The Settlement Amount shall be paid to Citibank NA 666 Fifth Avenue New York, NY 10103, ABA 021000089, Credit Acct. #: 9955561100 Title of account: Kirby McInerney LLP Atty Escrow For Dey Iowa AWP, an escrow account established for the State by Kirby McInerney LLP, which shall not disburse the funds prior to dismissal of Dey from the Litigation as provided for in this Agreement. The Parties note that the United States will receive a portion of the Settlement Amount (“Federal Amount”). The apportionment of the Settlement Amount between the State and the United States is to be handled between them. Within 180 days of the Effective Date, the State will (i) calculate the Federal Amount, (ii) pay the Federal Amount to the United States, and (iii) notify Dey of both the amount and payment when made.

The State’s Release of Dey

5. Subject to Dey paying all sums required by paragraph four (4) of this Agreement, the State does hereby fully and finally release Dey, its present and former parent corporation(s),

Dey's present and former subsidiaries and affiliates, including, without limitation, Merck KGaA, Merck Santé S.A.S., Merck S.A., EMD Inc., (collectively "Merck"), Mylan Inc. (formerly known as Mylan Laboratories Inc.), Mylan Pharmaceuticals Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., (collectively "Mylan") their predecessors, successors, and assigns as well as their current and former directors, officers, employees, agents and shareholders (collectively, the "Dey Released Parties") from any civil or administrative (i) claim, (ii) action, (iii) suit or (iv) proceeding the State has or may have or could have asserted in the future under any source of law for the Covered Conduct. Merck, as defined herein, does not refer to or include Merck & Co., Inc. (a New Jersey corporation whose principal place of business is located at One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889-0100), or any other entity that is a defendant in the Litigation.

6. Notwithstanding the foregoing, it is acknowledged that Merck KGaA, Merck Santé S.A.S., Merck S.A., and EMD, Inc. have not appeared in the Litigation, are not parties to this Agreement, and they shall not be deemed to have invoked the benefit of Iowa laws, or the privilege of doing business in Iowa, or otherwise to have submitted to jurisdiction in Iowa or any other forum within the United States for any purpose by reason of being identified as intended beneficiaries of this Agreement. This Release shall only release Mylan with respect to the Covered Conduct by Dey, but shall not release Mylan with respect to their own conduct.

7. The payment of all amounts required by paragraph four (4) of this Agreement fully discharges the Dey Released Parties from any obligation to pay additional restitution and compensatory damages, civil penalties, and costs and expenses of litigation, including attorneys' fees, to the State for the Covered Conduct. The State shall not initiate or prosecute civil litigation

against the Dey Released Parties based on the Covered Conduct. The Parties agree that this Agreement is not punitive in purpose or effect.

8. In consideration of the obligations of Dey set forth in this Agreement, conditioned on Dey's payment in full of all amounts required by this Agreement, the State agrees to release and refrain from instituting, directing, recommending or maintaining any action seeking Dey's exclusion from Iowa Medicaid for the Covered Conduct.

9. Notwithstanding any other provisions of this Agreement, specifically reserved and excluded from the scope and terms of this Agreement, and from the scope and terms of any release, are any and all of the following:

- a. Any claims based upon such obligations as are created by this Agreement;
- b. Any claims relating to the calculation of rebates paid to the State under any federal or state health care program or any other law or contract;
- c. Any liability of any sort under State revenue codes;
- d. Any express or implied warranty claims or other claims for defective or deficient products or services, including quality of goods and services, provided by Dey;
- e. The subrogation rights to claims for personal injury or property damage arising from usage by a participant in the Iowa Medicaid Program of any of the Covered Drugs;
- f. Any claims based on a failure to deliver items or services due;
- g. Any claims based on the marketing of mislabeled or off label products; and
- h. Claims of natural persons or consumers, or claims the State could assert on behalf of such natural persons or consumers, including for co-payments or co-insurance under Medicare Part B, occurring prior to the Effective Date of this Agreement. Notwithstanding the foregoing,

the State covenants not to sue Dey based on the claims reserved from the scope of the State's release by this subparagraph (h) if such claims are based upon the Covered Conduct.

Dey's Release of the State

10. Dey fully and finally releases the State, its agencies, employees, servants, attorneys and agents from any claims (including attorneys fees, costs, and expenses of every kind and however denominated) which Dey has asserted, could have asserted or may assert against the State, its agencies, employees, servants, attorneys and agents, related to the Covered Conduct and the State's investigation and prosecution thereof.

Dismissal of Action

11. Within three business days of receipt of the Settlement Amount, the State shall file with the court a Notice of Dismissal of Dey from the Litigation, with prejudice and with each Party bearing its own costs in connection with such dismissal.

Notice to Parties

12. Unless otherwise stated in writing subsequent to the Effective Date of this Agreement, all notifications and communications made pursuant to this Agreement shall be submitted to the entities listed below:

- a. For the State for all purposes:

Attorney General Tom Miller
Eric Tabor
Iowa Department of Justice
1305 E. Walnut, 2d Floor
Hoover Bldg.
Des Moines, IA 50319

Joanne M. Cicala, Esq.
Daniel Hume, Esq.
Kirby McInerney LLP
825 Third Avenue
New York, NY 10022

b. For Dey for all purposes:

Pamela R. Marrs
Senior Vice-President and Chief Financial Officer
Dey, L.P.
2751 Napa Valley Corporate Drive
Napa, California 94558

Paul F. Doyle, Esq.
Kelley Dye & Warren LLP
101 Park Avenue
New York, New York 10178

Miscellaneous Provisions

13. This Agreement, including any and all attachments or exhibits, constitutes the complete agreement between the State and Dey and may not be amended except by a writing signed by the State and Dey.

14. This Agreement shall be equally binding on the successors, transferees and assigns of each Party.

15. Nothing in this Agreement shall relieve Dey of its other obligations under applicable federal, state and local law.

16. The parties agree that this Agreement is freely and voluntarily entered into without any degree of duress or compulsion whatsoever.

17. Nothing in this Agreement shall be construed to create a waiver of the State's sovereign immunity.


18. Except as expressly set forth in paragraph six (6) of this Agreement, this Agreement shall neither create nor affect any rights of persons, or private or governmental entities or litigants, who are not parties to this Agreement. There are no third party beneficiaries to this Agreement.

19. Except as otherwise provided herein, each party to this Agreement shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement.
20. The laws of the State shall govern and determine all matters arising out of or in connection with this Agreement without regard to the conflict of law provisions of State law. Any and all litigation commenced in connection with this Agreement shall be brought and maintained solely in a court of competent jurisdiction located in Des Moines, IA.
21. The bold-faced paragraph captions in this Agreement are for convenience only and do not add to, detract from or change the substantive language or terms of this Agreement.
22. The undersigned individuals signing this Agreement on behalf of Dey represent and warrant that they are duly authorized by Dey to execute this Agreement.
23. The undersigned individuals signing this Agreement on behalf of the State represent that they are signing this Agreement in their official capacities and that they are duly authorized to execute this Agreement.
24. The State and Dey agree that should any nonmaterial portion or portions of this Agreement be found to be void, unenforceable or otherwise invalid by any court of competent jurisdiction after the exhaustion of all rights to appeal, the entire Agreement shall not be nullified and such invalid portion or portions shall be severed from the remainder of the Agreement as if they had never been entered into and the remainder of the Agreement shall be enforced.
25. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which shall be deemed to constitute one and the same Agreement.
26. The Effective Date of this Agreement shall be the date upon which all of the Parties below have executed this Agreement.

27. Neither Party to this Agreement shall be considered the drafter of this Agreement nor any included provision for the purpose of any statute, case law or rule of construction that would or might cause any provision to be construed against the drafter.

IN WITNESS WHEREOF, the State and Dey set their hands and seals on the dates set forth below:


Tom Miller
Attorney General of Iowa



Date: 11-9-09

Dey, L.P. and Dey, Inc.

By



Pamela R. Marrs
Senior Vice-President and Chief Financial Officer

Date: 10/20/09

APPENDIX A

DRUG NAME	NDC
Accuneb® 0.21mg/mL	49502-0692-03
Accuneb® 0.42mg/mL	49502-0693-03
Acetylcysteine 100mg/mL	49502-0181-04
Acetylcysteine 100mg/mL	49502-0181-10
Acetylcysteine 100mg/mL	49502-0181-30
Acetylcysteine 200mg/mL	49502-0182-00
Acetylcysteine 200mg/mL	49502-0182-04
Acetylcysteine 200mg/mL	49502-0182-10
Acetylcysteine 200mg/mL	49502-0182-30
Ace® Aerosol Cloud Enhancer	49502-0203-01
Ace® Holding Chamber	4135-3080-10
Ace® Holding Chamber Hospital Pack	49502-3080-60
Ace® Plastic Adapters	4135-3070-10
Albuterol 90mcg	49502-0303-17
Albuterol 90mcg	49502-0303-27
Albuterol 90mcg	49502-0333-17
Albuterol 90mcg	49502-0333-27
Albuterol Sulfate 0.83mg/mL	49502-0697-03
Albuterol Sulfate 0.83mg/mL	49502-0697-24
Albuterol Sulfate 0.83mg/mL	49502-0697-29
Albuterol Sulfate 0.83mg/mL	49502-0697-30
Albuterol Sulfate 0.83mg/mL	49502-0697-33
Albuterol Sulfate 0.83mg/mL	49502-0697-60
Albuterol Sulfate 0.83mg/mL	49502-0697-61
Albuterol Sulfate 2mg/5mL	49502-0795-16
Albuterol Sulfate 5mg/mL	49502-0105-01
Albuterol Sulfate 5mg/mL	49502-0196-20
Alprazolam 0.25mg	49502-0405-01

APPENDIX A

DRUG NAME	NDC
Alprazolam 0.25mg	49502-0405-05
Alprazolam 0.5mg	49502-0406-01
Alprazolam 0.5mg	49502-0406-05
Alprazolam 1mg	49502-0407-01
Alprazolam 1mg	49502-0407-05
Astech® Peak Flow Meter	49502-0200-01
Astech® Peak Flow Meter	4135-3070-10
Astech® Peak Flow Meter Adapter For Mouthpiece	49502-0202-12
Astech® Peak Flow Meter Adapter For Mouthpiece	4135-3070-75
Astech® Peak Flow Meter Disposable Mouthpiece	49502-0201-01
Astech® Peak Flow Meter Disposable Mouthpiece	4135-3070-70
Astech® Peak Flow Meter Disposable Mouthpiece	4135-0202-80
Astech® Peak Flow Meter Disposable Mouthpiece	4135-3070-85
Astech® Peak Flow Meter Hospital Pack	4135-3070-25
Astech® Peak Flow Meter Disposable Mouthpiece	49502-0202-48
Astech® Peak Flow Meter Disposable Mouthpiece	49502-0202-99
Atenolol 100mg	49502-0401-01
Atenolol 50mg	49502-0400-01
Atropine Sulfate 2mg/mL	49502-0074-12
Atropine Sulfate 5mg/mL	49502-0071-12
Balanced Salt	49502-0111-15
Cromolyn Sodium 20mg/2mL	49502-0689-02
Cromolyn Sodium 20mg/2mL	49502-0689-12
Cromolyn Sodium 20mg/2mL	49502-0689-61
Curosurf® 120mg/1.5	49502-0125-01
Curosurf® 120mg/1.5	49502-0180-01
Curosurf® 240mg/3mL	49502-0125-03
Curosurf® 240mg/3mL	49502-0180-03

APPENDIX A

DRUG NAME	NDC
Cyanokit 5g	49502-0550-02
Dey Occular Irrigating Cannula	49502-0100-26
Dey Occular Irrigating Cannula	49502-0100-27
Dey-Dose (Epinephrine) 11.25mg/mL	49502-0058-14
Dey-Dose (Isoetharine Hcl) 10mg/mL	49502-0052-20
Dey-Dose (Isoetharine Hcl) 10mg/mL	49502-0056-12
Dey-Dose (Isoetharine Hcl) 10mg/mL	49502-0056-14
Dey-Dose (Isoetharine Hcl) 10mg/mL	49502-0501-10
Dey-Dose (Isoetharine Hcl) 10mg/mL	49502-0501-30
Dey-Dose Metaproterenol Sulf 5pc	49502-0053-30
Dey-Lube	49502-0116-01
Dey-Mist Adapter	49502-0090-00
Dey-Mist Nebulizer	49502-0090-01
Dey-Mist Nebulizer Set	49502-0090-05
Dey-Mist Nebulizer Set	49502-0090-06
Dey-Sol	49502-0110-15
Dey-Vial (Sodium Chloride) 0.45%	49502-0020-03
Dey-Vial (Sodium Chloride) 0.45%	49502-0020-05
Dey-Vial (Sodium Chloride) 0.45%	49502-0020-10
Dey-Vial (Sodium Chloride) 10%	49502-0041-10
Dey-Vial (Sodium Chloride) 3%	49502-0040-10
Dey-Vial (Water)	49502-0010-03
Dey-Vial (Water)	49502-0010-05
Dey-Vial (Water)	49502-0010-10
Dey-Wash 0.9%	49502-0282-20
Duoneb® 2.5-0.5/3	49502-0672-30
Duoneb® 2.5-0.5/3	49502-0672-31
Duoneb® 2.5-0.5/3	49502-0672-60

APPENDIX A

DRUG NAME	NDC
Easivent®	49502-0207-01
Easivent®	49502-0207-25
Easivent®	49502-0208-01
Easivent®	49502-0208-02
Easivent®	49502-0208-03
Emsam Patch, Transdermal, 6 mg/24 hr	49502-0900-30
Emsam Patch, Transdermal, 9 mg/24 hr	49502-0901-30
Emsam Patch, Transdermal, 12 mg/24 hr	49502-0902-30
Epi EZPen® Jr. Auto-Injector w/ Release Button & Trainer (Epinephrine)	00268-0304-01
Epi EZPen® Jr. Auto-Injector w/ Release Button & Trainer (Epinephrine)	00268-0303-01
EpiPen® Trainer	49502-0500-00
EpiPen® 0.3mg/0.3	00268-0301-01
EpiPen® 0.3mg/0.3	49502-0500-01
EpiPen® 0.3mg/0.3	49502-0500-02
EpiPen® Jr. 0.15mg/0.3	00268-0302-01
EpiPen® Jr. 0.15mg/0.3	49502-0501-01
EpiPen® Jr. 0.15mg/0.3	49502-0501-02
EpiPen® Trainer	00268-0301-00
Euthyrox (Levothyroxine Sodium Tabs Usp) 100 mcg	63254-0439-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 100 mcg	63254-0439-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 112 mcg	63254-0440-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 112 mcg	63254-0440-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 125 mcg	63254-0441-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 125 mcg	63254-0441-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 150 mcg	63254-0442-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 150 mcg	63254-0442-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 175 mcg	63254-0443-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 175 mcg	63254-0443-10

APPENDIX A

DRUG NAME	NDC
Euthyrox (Levothyroxine Sodium Tabs Usp) 200 mcg	63254-0444-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 200 mcg	63254-0444-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 25 mcg	63254-0435-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 25 mcg	63254-0435-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 300 mcg	63254-0445-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 300 mcg	63254-0445-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 50 mcg	63254-0436-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 50 mcg	63254-0436-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 75 mcg	63254-0437-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 75 mcg	63254-0437-10
Euthyrox (Levothyroxine Sodium Tabs Usp) 88 mcg	63254-0438-01
Euthyrox (Levothyroxine Sodium Tabs Usp) 88 mcg	63254-0438-10
Hydrocodone w/Acetaminophen 5-500mg	49502-0415-01
Hydrocodone w/Acetaminophen 5-500mg	49502-0415-05
Hydrocodone w/Acetaminophen 7.5-650mg	49502-0417-01
Hydrocodone w/Acetaminophen 7.5-650mg	49502-0417-05
Hydrocodone w/Acetaminophen 7.5-750mg	49502-0416-01
Hydrocodone w/Acetaminophen 7.5-750mg	49502-0416-05
Ipratropium Bromide 0.2mg/mL	49502-0685-03
Ipratropium Bromide 0.2mg/mL	49502-0685-24
Ipratropium Bromide 0.2mg/mL	49502-0685-29
Ipratropium Bromide 0.2mg/mL	49502-0685-30
Ipratropium Bromide 0.2mg/mL	49502-0685-31
Ipratropium Bromide 0.2mg/mL	49502-0685-33
Ipratropium Bromide 0.2mg/mL	49502-0685-60
Ipratropium Bromide 0.2mg/mL	49502-0685-61
Ipratropium Bromide 0.2mg/mL	49502-0685-62
Ipratropium Bromide 21mcg	49502-0785-30

APPENDIX A

DRUG NAME	NDC
Ipratropium Bromide 42mcg	49502-0786-15
Isoetharine HCL 0.8mg/mL	49502-0061-03
Isoetharine HCL 0.8mg/mL	49502-0661-03
Isoetharine HCL 1.7mg/mL	49502-0060-03
Isoetharine HCL 1.7mg/mL	49502-0660-03
Isoetharine HCL 10mg/mL (Dey-Dose® Concentrate)	49502-0052-12
Isoetharine HCL 10mg/mL (Dey-Dose® Concentrate)	49502-0052-14
Isoetharine HCL 1mg/mL	49502-0064-05
Isoetharine HCL 1mg/mL	49502-0664-05
Isoetharine HCL 2.5mg/mL	49502-0059-02
Isoetharine HCL 2.5mg/mL	49502-0659-02
I-Sol Balanced Salt	49502-0110-20
I-Sol Balanced Salt	49502-0111-20
I-Sol Balanced Salt	49502-0112-00
Isoproterenol HCL 5mg/mL	49502-0057-12
Metaproterenol Sulfate 4mg/mL	49502-0678-03
Metaproterenol Sulfate 4mg/mL	49502-0678-24
Metaproterenol Sulfate 50mg/mL	49502-0055-13
Metaproterenol Sulfate 50mg/mL	49502-0055-30
Metaproterenol Sulfate 50mg/mL	49502-0155-30
Metaproterenol Sulfate 6mg/mL	49502-0676-03
Metaproterenol Sulfate 6mg/mL	49502-0676-24
Mucosol 100mg/mL	49502-0081-04
Mucosol 100mg/mL	49502-0081-10
Mucosol 100mg/mL	49502-0081-30
Mucosol 200mg/mL	49502-0082-00
Mucosol 200mg/mL	49502-0082-04
Mucosol 200mg/mL	49502-0082-10

APPENDIX A

DRUG NAME	NDC
Mucosol 200mg/mL	49502-0082-30
Nebu-Sol 0.9%	49502-0503-00
Perforomist®	49502-0605-61
Pindolol 10mg	49502-0410-01
Pindolol 5mg	49502-0409-01
Piroxicam 20mg	49502-0403-01
Piroxicam 20mg	49502-0403-05
Racepinephrine 1.125%	49502-0054-14
Silver Nitrate 1%	49502-0114-14
Sodium Chloride (Dey-Pak®) 0.9%	49502-0630-01
Sodium Chloride (Dey-Pak®) 0.9%	49502-0630-10
Sodium Chloride (Dey-Pak®) 0.9%	49502-0630-15
Sodium Chloride 0.45%	49502-0620-03
Sodium Chloride 0.45%	49502-0620-05
Sodium Chloride 0.45%	49502-0820-03
Sodium Chloride 0.45%	49502-0820-05
Sodium Chloride 0.9%	49502-0030-03
Sodium Chloride 0.9%	49502-0030-05
Sodium Chloride 0.9%	49502-0030-10
Sodium Chloride 0.9%	49502-0030-20
Sodium Chloride 0.9%	49502-0501-20
Sodium Chloride 0.9%	49502-0630-03
Sodium Chloride 0.9%	49502-0630-05
Sodium Chloride 0.9%	49502-0830-03
Sodium Chloride 0.9%	49502-0830-05
Sodium Chloride 0.9%	49502-0830-15
Sodium Chloride 0.9%	49502-0830-50
Sodium Chloride 0.9%	49502-0831-03

APPENDIX A

DRUG NAME	NDC
Sodium Chloride 0.9%	49502-0831-05
Sodium Chloride 10%	49502-0641-15
Sodium Chloride 3%	49502-0640-15
Theophylline Anhydrous 100mg	49502-0431-01
Theophylline Anhydrous 200mg	49502-0432-01
Theophylline Anhydrous 200mg	49502-0432-05
Theophylline Anhydrous 300mg	49502-0433-01
Theophylline Anhydrous 300mg	49502-0433-05
Theophylline Anhydrous 300mg	49502-0433-10
Triazolam 0.125mg	49502-0412-01
Triazolam 0.25mg	49502-0413-01
Water For Inhalation	49502-0610-03
Water For Inhalation	49502-0610-05
Water For Inhalation	49502-0810-03
Water For Inhalation	49502-0810-05